BiotechTube
VLP Therapeutics

VLP Therapeutics

Gaithersburg, United States· Est.
vlptherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $20M

Overview

VLP Therapeutics is a clinical-stage biotech advancing a novel vaccine platform centered on self-amplifying RNA (saRNA) with modified nucleosides, such as 5-methylcytidine, to improve safety and immunogenicity. The company has a diversified pipeline including COVID-19, malaria, and dengue vaccines, as well as cancer immunotherapies, supported by partnerships and non-dilutive funding from entities like the Gates Foundation. With operations in the US and Japan, VLPT is positioning itself as a player in the next wave of mRNA and replicon vaccine technology, aiming for broader and more durable immune responses.

Infectious DiseasesOncology

Technology Platform

Proprietary self-amplifying RNA (saRNA/replicon) platform utilizing modified nucleosides (e.g., 5-methylcytidine) for improved safety/immunogenicity, and an i-αVLP (intelligent alphavirus-like particle) platform for surface antigen display.

Funding History

2
Total raised:$20M
Series A$15M
Seed$5M

Opportunities

The company's dose-sparing, low-reactogenicity saRNA platform is well-suited for both pandemic response and diseases prevalent in low-resource settings, aligning with global health priorities.
Partnerships with the Gates Foundation and AI-driven diagnostics create non-dilutive funding and potential for highly targeted clinical development, particularly in oncology.

Risk Factors

The company faces significant competition from large, established mRNA players and must prove clinical superiority in later-stage trials.
As a private, pre-revenue biotech, it carries execution and financing risk, dependent on raising capital to advance its pipeline through costly clinical development.

Competitive Landscape

VLPT competes in the crowded mRNA vaccine space against giants like Moderna and Pfizer/BioNTech, as well as other saRNA developers (e.g., Gritstone bio, Arcturus). Its differentiation hinges on its 5mC modification for improved tolerability. In malaria and cancer vaccines, it faces competition from both large pharma and specialized biotechs, but its platform technology offers a novel approach.

More companies in United States →